1. Home
  2. LEGN vs HLNE Comparison

LEGN vs HLNE Comparison

Compare LEGN & HLNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEGN
  • HLNE
  • Stock Information
  • Founded
  • LEGN 2014
  • HLNE 1991
  • Country
  • LEGN United States
  • HLNE United States
  • Employees
  • LEGN N/A
  • HLNE N/A
  • Industry
  • LEGN Biotechnology: Pharmaceutical Preparations
  • HLNE Investment Managers
  • Sector
  • LEGN Health Care
  • HLNE Finance
  • Exchange
  • LEGN Nasdaq
  • HLNE Nasdaq
  • Market Cap
  • LEGN 7.0B
  • HLNE 6.0B
  • IPO Year
  • LEGN 2020
  • HLNE 2017
  • Fundamental
  • Price
  • LEGN $39.70
  • HLNE $151.46
  • Analyst Decision
  • LEGN Strong Buy
  • HLNE Hold
  • Analyst Count
  • LEGN 12
  • HLNE 7
  • Target Price
  • LEGN $79.50
  • HLNE $163.00
  • AVG Volume (30 Days)
  • LEGN 976.3K
  • HLNE 571.8K
  • Earning Date
  • LEGN 03-10-2025
  • HLNE 02-04-2025
  • Dividend Yield
  • LEGN N/A
  • HLNE 1.29%
  • EPS Growth
  • LEGN N/A
  • HLNE 66.80
  • EPS
  • LEGN N/A
  • HLNE 5.42
  • Revenue
  • LEGN $520,183,000.00
  • HLNE $691,656,000.00
  • Revenue This Year
  • LEGN $121.13
  • HLNE $25.46
  • Revenue Next Year
  • LEGN $65.25
  • HLNE $8.07
  • P/E Ratio
  • LEGN N/A
  • HLNE $27.95
  • Revenue Growth
  • LEGN 122.96
  • HLNE 41.16
  • 52 Week Low
  • LEGN $30.17
  • HLNE $103.42
  • 52 Week High
  • LEGN $70.13
  • HLNE $203.72
  • Technical
  • Relative Strength Index (RSI)
  • LEGN 64.82
  • HLNE 41.64
  • Support Level
  • LEGN $34.36
  • HLNE $150.56
  • Resistance Level
  • LEGN $36.39
  • HLNE $160.28
  • Average True Range (ATR)
  • LEGN 1.67
  • HLNE 5.96
  • MACD
  • LEGN 0.34
  • HLNE -0.71
  • Stochastic Oscillator
  • LEGN 94.68
  • HLNE 8.33

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

About HLNE Hamilton Lane Incorporated

Hamilton Lane Inc is a private market investment solutions provider in the United States. It works with its clients to conceive, structure, build out, manage and monitor portfolios of private markets funds and direct investments, and it helps them access a set of such investment opportunities around the world. The company offers a range of investment solutions across a range of private markets, including private equity, private credit, real estate, infrastructure, natural resources, growth equity, venture capital and impact. The company generate revenues mainly from management and advisory fees.

Share on Social Networks: